Tricyclic antidepressants (TCAs) have been reported to interact with the opioid system, but their pharmacological activity at opioid receptors has not yet been elucidated. In the present study, we investigated the actions of amoxapine, amitriptyline, nortriptyline, desipramine, and imipramine at distinct cloned and native opioid receptors. In Chinese hamster ovary (CHO) cells expressing ␦-opioid receptors (CHO/DOR), TCAs displaced [3H]naltrindole binding and stimulated guanosine 5Ј-O-(3-[
cells expressing -opioid receptors (CHO/KOR), TCAs, but not amoxapine, exhibited higher receptor affinity and more potent stimulation of [
35 S]GTP␥S binding than in CHO/DOR and effectively inhibited cyclic AMP accumulation. Amitriptyline regulated ERK1/2 phosphorylation and activity in CHO/KOR and C6 glioma cells endogenously expressing -opioid receptors, and this effect was attenuated by the -opioid antagonist nor-binaltorphimine. In rat nucleus accumbens, amitriptyline slightly inhibited adenylyl cyclase activity and counteracted the inhibitory effect of the full agonist trans-(Ϫ) -3,4dichloro-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexyl]benzeneacetamide (U50,488). At the cloned -opioid receptor, TCAs showed low affinity and no significant agonist activity. These results show that TCAs differentially regulate opioid receptors with a preferential agonist activity on either ␦ or subtypes and suggest that this property may contribute to their therapeutic and/or side effects.
Although the inhibition of presynaptic reuptake of monoamines is considered to be the primary mechanism of action of tricyclic antidepressants (TCAs), it is well established that these drugs can act on multiple molecular targets by affecting the activity of distinct neurotransmitter receptor systems and ion channels (Baldessarini, 2006) . These secondary actions have been generally related to TCAs' adverse side effects, although some of them have been proposed to contribute to the therapeutic activity.
An interaction with the opioid system has long been shown to be involved in the analgesic and mood-elevating effects of TCAs. A number of studies have reported that the antinociceptive effects of TCAs are reversed by opioid receptor antagonists (Biegon and Samuel, 1980; Gray et al., 1998; Marchand et al., 2003; Benbouzid et al., 2008a,b) and that TCAs potentiate morphine-induced analgesia both in animals (Hamon et al., 1987) and in humans (Micó et al., 2006) . In animal behavioral tests predictive of antidepressant effects in humans, such as the forced swimming and learned helplessness tests, the effects of TCAs have been found to be antagonized by blockade of opioid receptors, indicating the possible participation of opioid neurotransmission in the antidepressant activity of these drugs (Devoize et al., 1982; Tejedor-Real et al., 1995; Besson et al., 1999) .
Although these studies implicate opioid mechanisms in the pharmacological activity of TCAs, the mode of action of these drugs on the opioid system has not been fully clarified. Some studies have reported that long-term antidepressant use increases enkephalin levels in different brain areas (De Felipe et al., 1985; Hamon et al., 1987) , whereas others observed no change or a decrease (Herman et al., 1986; Kurumaji et al., 1988) . Radioligand binding studies examining the interactions of TCAs with opioid receptors also yielded contradictory results. For example, in vivo administration of TCAs has been found to cause a decrease, an increase, and no change in opioid receptor density in different brain areas (StengaardPedersen and Schou, 1986; Hamon et al., 1987; Chen and Lawrence, 2004) . Moreover, TCAs have been reported to be either devoid of activity at brain opioid receptors (Hall and Ogren, 1981) or capable of inhibiting opioid receptor binding at pharmacologically relevant concentrations (Biegon and Samuel, 1980; Isenberg and Cicero, 1984; Wahlström et al., 1994) . Thus, whether these drugs can directly act on opioid receptors and whether the distinct opioid receptor subtypes are differentially affected by TCAs still remain unresolved issues.
In the present study, we investigated the action of the TCAs amoxapine, amitriptyline, nortriptyline, desipramine, and imipramine at cloned human ␦-, -, and -opioid receptors individually expressed in Chinese hamster ovary (CHO) cells. Moreover, the effects of some of these drugs at opioid receptors endogenously expressed in C6 glioma cells, rat dorsal striatum and nucleus accumbens, and postmortem human frontal cortex were also examined.
were generated as described previously (Olianas et al., 2006) . CHO cells stably expressing the human muscarinic M 2 (CHO/M 2 ) and M 4 (CHO/M 4 ) were grown as previously reported (Olianas et al., 1999) . CHO/DOR cells were maintained in the presence of 350 g/ml hygromycin (Invitrogen), whereas for the other recombinant cell lines the growth medium contained 400 g/ml geneticin (Invitrogen). C6 rat glioma cells (European Collection of Cell Cultures, Porton Down, Wiltshire, UK) were grown in Ham's F-12 medium supplemented with 2 mM L-glutamine, 0.5% penicillin/streptomycin, and 10% fetal calf serum in a humidified 95% air and 5% CO 2 at 37°C.
Cell Membrane Preparation. Cells were washed with ice-cold phosphate-buffered saline (PBS), pH 7.4; scraped into an ice-cold buffer containing 10 mM HEPES/NaOH, pH 7.4, and 1 mM EDTA; and lysed with a Dounce tissue grinder. The cell lysate was centrifuged at 1000g for 2 min at 4°C. The supernatant was collected and centrifuged at 32,000g for 20 min at 4°C. The pellet was resuspended in homogenization buffer at a protein concentration of 1.0 to 1.5 mg/ml and stored in aliquots at Ϫ80°C.
Cell Treatments and Cell Extract Preparation. Cells were serum-starved for 24 h (CHO cells) or 48 h (C6 glioma cells) and then exposed to the test agents for the indicated time periods, washed with ice-cold PBS, and lysed by scraping into PBS containing 0.1% SDS, 1% Nonidet P40, 0.5% sodium deoxycholate, 2 mM EDTA, 2 mM EGTA, 4 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 10 mM sodium fluoride, 20 nM okadaic acid, 0.1% phosphatase inhibitor mixture 1, and 1% protease inhibitor mixture. The samples were sonicated for 5 s in an ice bath and stored at Ϫ80°C. Aliquots of cell extracts were taken for protein determination. Protein content was determined by the method of Bradford (1976) using bovine serum albumin (BSA) as a standard.
Dissection of Brain Regions and Membrane Preparation. Male Sprague-Dawley rats (200 -300 g) were used. Animals were maintained in a 12-h light/dark cycle with food and water ad libitum. Experiments were performed in accordance with the European Communities Council Directive of November 24, 1986 (86/609/EEC) and with the principles of Laboratory Animal Care in Italy (D.L. 116/92). Rats were killed by decapitation, and the dorsal striatum and nucleus accumbens were rapidly microdissected from 300-m brain coronal slices as described previously (Olianas et al., 2006) . Landmarks used for the dissection of the nucleus accumbens were the anterior commissure, the olfactory and lateral ventricles, the corpus striatum, the septal nuclei, and the olfactory tubercle.
Human frontal cortex tissue was obtained at autopsy from three male subjects (age 35-68 years, mean 56 years) within 26 to 36 h after death. The subjects had no history of neurological or psychiatric disease. The tissue was immediately frozen at Ϫ80°C and stored in liquid nitrogen. The specimens were provided by Professor R. Ambu (Department of Cytomorphology, University of Cagliari, Italy). The study was approved by the local ethics committee.
Freshly dissected or frozen tissue samples were homogenized in an ice-cold buffer containing 10 mM HEPES-NaOH, 1 mM EGTA, and 1 mM MgCl 2 , pH 7.40, using a Teflon-glass tissue grinder (Kontes, Vineland, NJ). The homogenate was centrifuged at 27,000g for 20 min at 4°C. The pellet was resuspended in the same buffer at a protein concentration of 0.8 to 1.0 mg/ml and used immediately for adenylyl cyclase assays or stored at Ϫ80°C for binding assays.
Assay of [ 35 S]GTP␥S Binding. The binding of [ 35 S]GTP␥S was assayed in a reaction mixture (final volume 100 l) containing 25 mM HEPES/NaOH, pH 7.4, 10 mM MgCl 2 , 1 mM EDTA, 150 mM KCl, 10 kallikrein inhibitor units of aprotinin, and 1.0 nM [ 35 S]GTP␥S. The GDP concentration was optimized for each receptor system and was 30 M for CHO/KOR and CHO/DOR, 10 M for CHO/MOR-1, and 50 M for rat and human brain membranes. Membranes (2-4 g of protein) were preincubated for 20 min at 30°C with the test compounds. For each compound, control samples received an equal volume (10 l) of vehicle. The reaction was started by the addition of [
35 S]GTP␥S and continued for 40 min at 30°C. The incubation was terminated by the addition of 5 ml of ice-cold buffer containing 10 mM HEPES/NaOH, pH 7.4, and 1.0 mM MgCl 2 , immediately followed by rapid filtration on glass fiber filters (GF/C; Whatman International Ltd, Maidstone, UK). The filters were washed twice with 5 ml of buffer, and the radioactivity trapped was determined by liquid scintillation spectrometry. Reactions were terminated by filtration through Whatman GF/C filters presoaked with 0.1% polyethylenimine, which were washed three times with 5 ml of ice-cold buffer containing 10 mM HEPES/NaOH, pH 7.4, and 1 mM MgCl 2 . The radioactivity trapped was determined by liquid scintillation spectrometry.
Assay of [ 3 H]Cyclic AMP Accumulation. CHO cells grown in 36-mm plastic dishes were incubated in Ham's F-12 medium containing 10 Ci/ml [ 3 H]adenine for 1 h at 37°C in an CO 2 incubator. Thereafter, the medium was removed, and the cells were incubated in an oxygenated Krebs-HEPES buffer containing 1 mM 3-isobutyl-1-methylxanthine for 10 min at 37°C. FSK (10 M) and the various test compounds were then added, and the incubation was continued for 10 min. Control samples were incubated in the presence of an equal volume of vehicle. The incubation was stopped by the aspiration of the medium and the addition of an ice-cold solution containing 6% (w/v) perchloric acid and 0.1 mM [
14 C]cyclic AMP (ϳ4000 cpm). After 30 min at ice-bath temperature, the solution was neutralized by the addition of ice-cold 0.6 M KOH and left on ice for an additional 30 min. After centrifugation at 20,000g for 5 min, the supernatant was collected, and [ 3 H]cyclic AMP was isolated by sequential chromatography on Dowex (Bio-Rad Laboratories, Hercules, CA) and alumina columns. The recovery of [ 3 H]cyclic AMP from each sample was corrected based on the recovery of [ 14 C]cyclic AMP. Assay of Adenylyl Cyclase Activity. The adenylyl cyclase activity was assayed in a reaction mixture (final volume 100 l) containing 50 mM HEPES/NaOH, pH 7.4, 2.3 mM MgCl 2 , 0.3 mM EGTA, 0.05 mM [␣- 32 P]ATP (150 cpm/pmol), 0.5 mM [ 3 H]cyclic AMP (80 cpm/nmol), 1 mM 3-isobutyl-1-methylxanthine, 5 mM phosphocreatine, 50 U/ml creatine phosphokinase, 100 M GTP, 50 g of BSA, 10 g of bacitracin, and 10 kallikrein inhibitor units of aprotinin. FSK was present at the final concentration of 10 M. The reaction was started by the addition of the tissue preparation (20 -25 g of protein) and was carried out at 25°C for 20 min. The reaction was stopped by the addition of 200 l of a solution containing 2% (w/v) SDS, 45 mM ATP, and 1.3 mM cyclic AMP, pH 7.5. Cyclic AMP was isolated by sequential chromatography on Dowex (Bio-Rad Laboratories) and alumina columns. The recovery of [ 32 P]cyclic AMP from each sample was calculated based on the recovery of [ 3 H]cyclic AMP. Assays were carried out in duplicate.
Western Blot Analysis. Aliquots of cell extracts containing equal amount of protein were subjected to SDS-polyacrylamide gel electrophoresis, and the proteins were electrophoretically transferred to polyvinylidene difluoride membranes (Hybond-P; GE Healthcare, Piscataway, NJ). The efficiency of the transfer was controlled by gel staining and by following the transfer of prestained protein standards. Nonspecific binding sites were blocked by incubation in 20 mM Tris-HCl, 137 mM NaCl, and 0.1% Tween 20, pH 7.6, containing 5% BSA for 1 h. After washing with Tris-buffered saline containing Tween 20, the membranes were incubated overnight at 4°C with one of the following primary antibodies: pERK1/2 (1:10,000); ERK1/2 (1:1000), pGSK-3␤ (1:1000), GSK (1:1000), pAkt (1:1000), or actin (1:1000). The membranes were then incubated with a horseradish peroxidase-conjugated secondary antibody (1:10,000), and immunoreactive bands were detected by using enhanced chemiluminescence (ECL) Plus and ECL Hyperfilm (GE Healthcare). The size of the immunoreactive bands was determined by using molecular weight standards detected with a specific antibody suitable for the ECL system (Santa Cruz Biotechnology, Inc.). Band densities were determined by densitometric analysis using Image Scanner III (GE Healthcare) and National Institutes of Health ImageJ software (Bethesda, MD). The optical density of phosphoprotein bands was normalized to the density of the corresponding total protein or actin band to yield the relative optical density value.
Assay of ERK1/2 Activity. ERK1/2 activity was measured by a nonradioactive kinase assay kit according to the manufacturer's instructions (Cell Signaling Technology Inc.). In brief, serum-starved C6 glioma cells were treated with the test drugs for the indicated time periods, washed with ice-cold PBS, and incubated for 5 min with ice-cold cell lysis buffer (25 mM Tris-HCl, pH 7.50, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerolphosphate, 1 mM sodium orthovanadate, and 1 g/ml leupeptin). An aliquot of each cell extract was incubated overnight with immobilized antibody against phospho-ERK1/2 with gentle rocking at 4°C. After immunoprecipitation, the pellets were suspended in kinase buffer (25 mM Tris-HCl, pH 7.50, 5 mM ␤-glycerolphosphate, 0.1 mM sodium orthovanadate, 2 mM dithiothreitol, and 10 mM MgCl 2 ) supplemented with 200 M ATP and 40 g/ml Elk-1 fusion protein as a substrate and incubated for 30 min at 30°C. The samples were then subjected to SDS-polyacrylamide gel electrophoresis and Western blotting using a rabbit polyclonal antiphospho-Elk-1 (Ser383) (pElk-1) antibody (1:1000). For each sample, an aliquot of the corresponding cell extract was analyzed for total ERK1/2 protein, and the optical density of the pElk-1 band was normalized to the density of the ERK1/2 bands.
Statistical Analysis. Results are reported as mean Ϯ S.E.M. Data from concentration-response curves were analyzed using GraphPad Software Inc. Prism (San Diego, CA), which yielded agonist concentration producing half-maximal effect (EC 50 values) and maximal effects (E max ). The percentage of maximal effect (% E max ) by the drugs at ␦-and -opioid receptors was calculated as E max of the agonist/E max of the reference full agonist (DPDPE or U50,488, respectively) ϫ 100. Saturation binding data were analyzed by the nonlinear curve-fitting program LIGAND, which provided ligand dissociation constant (K D ) and maximal binding capacity (B max ). Antagonist potencies were analyzed by nonlinear regression analysis. When increasing concentrations of antagonists in the presence of a fixed concentration of agonist were examined, the antagonist inhibitory constant (K i ) was calculated according to the equation: K i ϭ IC 50 /1 ϩ (A/EC 50 ), where IC 50 is the antagonist concentration producing half-maximal inhibition, A is the agonist concentration, and EC 50 is the agonist EC 50 value. When the effect of a fixed drug concentration in the presence of increasing agonist concentrations was examined, the K i value was calculated according to the equation: EC 50b ϭ EC 50a (1 ϩ I/K i ), where EC 50a and EC 50b are agonist EC 50 values in the absence and in the presence of the antagonist, respectively, and I is the concentration of the antagonist. Statistical analysis was performed by either Student's t test when comparing two groups or one-way analysis of variance (ANOVA) followed by either Dunnett's or Newman-Keuls post hoc tests when comparing more than two groups.
Results

Effects of TCAs in CHO/DOR. In CHO/DOR membranes, TCAs induced a complete displacement of [
3 H]NTIspecific binding (Fig. 1A) . The dibenzoxazepine amoxapine Opioid Receptor Activation by Antidepressants was the most potent with a K i value (2.3 M) approximately 12-to 20-fold lower than that of the other drugs ( Amoxapine behaved as a full agonist displaying a maximal effect equal to that of the selective ␦-opioid agonist DPDPE and a potency in the low micromolar range ( Table 1 ). The other TCAs tested were 23-to 47-fold less potent than amoxapine but, with the exception of desipramine, showed only slightly lower efficacies. Addition of the ␦-opioid receptor antagonist NTI (10 nM) completely antagonized the stimulatory effects elicited by the TCAs (Fig. 1D ). Each TCA, tested at the same concentration range, failed to significantly stimulate [
35 S]GTP␥S binding in membranes prepared from nontransfected CHO/K1 cells (result not shown). Moreover, each TCA (1-100 M) failed to affect [
35 S]GTP␥S binding in membranes prepared from either CHO/M 2 (B max ϭ 3200 Ϯ 500 fmol/mg protein) or CHO/M 4 (B max ϭ 3500 Ϯ 100 fmol/mg protein) cells, which were used as control for G i/ocoupled receptors expressed at similar densities (result not shown).
In intact CHO/DOR cells, amoxapine and amitriptyline inhibited FSK-stimulated cyclic AMP accumulation with EC 50 values of 3.4 Ϯ 0.5 and 16.2 Ϯ 0.8 M, respectively, and maximal effects corresponding to 41.1 Ϯ 3.2 and 43.5 Ϯ 4.5% decrease of control activity (p Ͻ 0.001), respectively ( Fig. 2A) . These effects were equal to approximately 72% of the maximal inhibitory response elicited by DPDPE (EC 50 ϭ 0.7 Ϯ 0.2 nM) and were completely antagonized by the addition of 10 nM NTI (Fig. 2B) .
Besides regulating cyclic AMP formation, ␦-opioid receptors have been shown to modulate other intracellular signaling pathways, such as ERK1/2 phosphorylation cascade and the phosphatidylinositol 3-kinase pathway (Tegeder and Geisslinger, 2004) . These pathways are known to regulate cell proliferation, differentiation, and neuronal survival and have been proposed to be molecular targets of antidepressants (Jope and Roh, 2006; Duman et al., 2007) . Treatment of CHO/DOR with amoxapine (10 M) caused a rapid increase of the phosphorylation of ERK1/2, Akt, and GSK-3␤, which peaked at 5 min and remained elevated for at least 30 min (Fig. 3, A and B) . Consistent with the stimulation of ERK1/2 activity, the drug induced a marked phosphorylation of S6 ribosomal protein (pS6rp), a downstream target of ERK1/2, which reached a plateau at approximately 15 min and lasted for at least 30 min. The stimulatory effects on ERK1/2 and GSK-3␤ phosphorylations were concentration-dependent with EC 50 values of 5.1 Ϯ 0.4 and 4.4 Ϯ 0.6 M, respectively, and completely antagonized by 10 nM NTI (Fig. 3, C-J) . Moreover, amoxapine (10 M) failed to affect ERK1/2 and GSK-3␤ phosphorylations in nontransfected CHO-K1 cells (result not shown). The maximal stimulations of ERK1/2 and GSK-3␤ phosphorylations corresponded to 8.0-and 2.4-fold increase of control values (p Ͻ 0.001), respectively, and were equal to 66 and 70% of the maximal stimulations elicited by DPDPE, respectively. At the concentrations tested, amoxapine failed to affect the levels of total ERK1/2 and GSK-3␤ proteins (Fig. 3, E, G, and I) .
Like amoxapine, amitriptyline caused a concentration-dependent stimulation of ERK1/2 and GSK-3␤ phosphorylation with EC 50 values of 10.7 Ϯ 0.9 and 9.0 Ϯ 0.5 M, respectively, and E max values corresponding to 550 Ϯ 70 and 90 Ϯ 10% increase of control values (p Ͻ 0.001), respectively (Fig.  4) . The addition of NTI (10 nM) significantly attenuated the stimulatory effect of amitriptyline on ERK1/2 phosphorylation and completely blocked the induction of GSK-3␤ phosphorylation elicited by the antidepressant (Fig. 4) .
Effects of Amoxapine in Rat and Human Brain. In membranes of rat dorsal striatum and nucleus accumbens, amoxapine maximally stimulated [
35 S]GTP␥S binding by 35 Ϯ 3% (p Ͻ 0.01) and 28 Ϯ 5% (p Ͻ 0.05) increase of control, respectively (E max values were equal to 51 and 39% of the DPDPE E max , respectively), with EC 50 values of 5.5 Ϯ 1.3 and 3.5 Ϯ 1.0 M, respectively (Fig. 5A ). The use of receptor subtype-selective antagonists indicated that the stimulatory effect of amoxapine (30 M) was mediated by ␦-opioid receptors. In fact, it was antagonized by NTI with a K i value of 25 Ϯ 5 pM, which is similar to the affinity of the antagonist for ␦-opioid receptors. In contrast, the selective -opioid receptor antagonist nor-BNI was severalfold less potent than NTI, displaying a K i of 3.2 Ϯ 0.8 nM (Fig. 5B ). This value is approximately 100-fold higher than nor-BNI affinity for the -opioid receptor and close to its affinity for ␦-opioid receptors (Metcalf and Coop, 2005) . The selective -opioid receptor antagonist CTAP failed to cause a significant inhibition up to 1 M (Fig. 5B) , a concentration that was sufficient to completely block the stimulatory effect elicited by the -opioid receptor agonist DAMGO (100 nM) (result not shown). None of the antagonists significantly affected [
35 S]GTP␥S binding per se. In rat nucleus accumbens, amoxapine inhibited FSKstimulated adenylyl cyclase activity (18 Ϯ 0.9% reduction of control activity, p Ͻ 0.05, equal to 68% of the DPDPE E max ) with an EC 50 of 4.5 Ϯ 0.7 M (Fig. 5C ). This effect was completely blocked by the addition of 3 nM NTI. Finally, in membranes of postmortem human frontal cortex amoxapine stimulated [
35 S]GTP␥S binding by 32 Ϯ 6% (p Ͻ 0.05; equal to 48% of DPDPE E max ) with an EC 50 value of 3.6 Ϯ 0.8 M (Fig. 5D ). This response also was blocked by the addition of 3 nM NTI (Fig. 5E) .
Effects of TCAs in CHO/KOR. In receptor binding assays, TCAs completely displaced specific [ 3 H]diprenorphine binding with a rank order of potencies opposite to that observed at CHO/DOR. In fact, amitriptyline, nortriptyline, desipramine, and imipramine showed K i values in the low micromolar range (1.8 -3.3 M), whereas amoxapine was much less potent ( Fig. 6A; Table 2 ). Scatchard analysis of In CHO/KOR membranes, TCAs elicited a concentrationdependent stimulation of [
35 S]GTP␥S binding with a rank order of potency consistent with their receptor affinity. Thus, amitriptyline, nortriptyline, desipramine, and imipramine showed EC 50 values between 1.5 and 4.8 M, whereas the amoxapine concentration-response curve did not reach a plateau at concentrations as high as 300 M (Fig. 6C) . The E max values of TCAs ranged from 76 to 85% of that displayed by the full -opioid agonist (Ϫ)-U50,488 (E max ϭ 183 Ϯ 8% increase of control value; EC 50 ϭ 0.60 Ϯ 0.08 nM) ( Fig. 6C ; Table 2 ). In CHO/KOR cells, amitriptyline, nortriptyline, desipramine, and imipramine inhibited FSK-stimulated cyclic AMP accumulation by approximately 50% with EC 50 values close to those observed in [
35 S]GTP␥S binding assays ( Fig. 6E ; Table 2 ). The TCA E max values corresponded to 70 to 78% of that of (Ϫ)-U50,488, which inhibited cyclic AMP accumulation by 72 Ϯ 6% with an EC 50 of 0.31 Ϯ 0.05 nM. In contrast, amoxapine displayed a weaker agonist activity and maximally inhibited cyclic AMP accumulation by 30% at 100 M (Fig. 6E) . Both functional responses elicited by TCAs were completely blocked by nor-BNI (100 nM), which had no effect per se (Fig. 6, D and F) .
In CHO/KOR cells, amitriptyline (1-50 M) induced a concentration-dependent stimulation of ERK1/2 phosphorylation with an EC 50 value of 4.5 Ϯ 0.8 M and an E max corresponding to 570 Ϯ 95% increase of control value (p Ͻ 0.001) (Fig. 7, A and B) . The addition of nor-BNI (100 nM) Fig. 3 . Amoxapine stimulates ERK1/2 and phosphatidylinositol 3-kinase signaling pathways in CHO/DOR cells. A, time course of amoxapineinduced phosphorylation of ERK1/2 (pERK1/2), pS6 ribosomal protein (pS6rp), Akt (pAkt), and GSK-3␤ (pGSK). Cells were incubated with amoxapine (10 M) for the indicated time periods, and phosphorylated proteins were measured in cell extracts by Western blot. B, densitometric analysis of pERK1/2, pS6rp, pAkt, and pGSK bands normalized to the density of actin. Values are reported as percentage of the corresponding vehicle-treated sample (zero time). Values are the mean Ϯ S.E.M. of three experiments. C, concentration-dependent stimulation of ERK1/2 phosphorylation by amoxapine. Cells were incubated in the presence of the indicated concentrations of amoxapine for 5 min, and pERK1/2 and total ERK1/2 were measured in the cell extracts. D, densitometric analysis of pERK1/2 normalized to the density of total ERK1/2. Values are reported as percentage of control and are the mean Ϯ S.E.M. of three experiments. E, antagonism of amoxapine-induced ERK1/2 phosphorylation by NTI. Cells were preincubated for 5 min with either vehicle or 10 nM NTI and then exposed to either vehicle or 10 M amoxapine for additional 5 min. effectively antagonized the stimulatory effect elicited by amitriptyline.
Effects of TCAs in C6 Glioma Cells. C6 glioma cells are known to endogenously express -opioid receptors coupled to stimulation of ERK1/2 phosphorylation (Bohn et al., 2000) . Moreover, it has been recently reported that in this cell line TCAs induced ERK1/2 activation through a monoamine-in- jpet.aspetjournals.org dependent mechanism (Hisaoka et al., 2007) . Therefore, it was of interest to investigate whether -opioid receptors could mediate the actions of TCAs on ERK1/2 signaling in this cell system. As shown in Fig. 7 , C and D, a brief exposure of C6 cells to amitriptyline (15 M) caused a stimulation of ERK1/2 phosphorylation, which corresponded to a 5.7-fold increase of control value (p Ͻ 0.001). The addition of nor-BNI (100 nM) reduced the amitriptyline stimulatory effect by 70% (p Ͻ 0.001). When ERK1/2 activity was measured after immunoprecipitation and determination of Elk-1phosphoryla-tion, it was found that amitriptyline (15 M) stimulated the kinase activity by 4.8-fold (p Ͻ 0.001) (Fig. 7, E and F) and that this response was reduced by approximately 50% after pretreatment with 100 nM nor-BNI (p Ͻ 0.01).
Effects of Amitriptyline in Rat Nucleus Accumbens. In membranes of rat nucleus accumbens, amitriptyline caused a slight but significant inhibition of FSK-stimulated cyclic AMP formation with an EC 50 value of 6.2 Ϯ 0.8 M and an E max corresponding to 12 Ϯ 3% decrease of control activity (p Ͻ 0.05) (Fig. 8A) . The inhibitory effect was completely antagonized by 10 nM nor-BNI (result not shown). When combined with (Ϫ)-U50,488 (300 nM), amitriptyline caused a concentration-dependent reduction of the inhibitory effect elicited by the full -opioid agonist, bringing the enzyme activity to the level determined by its maximal effect (Fig.  8A ). In the same membrane preparations, (Ϫ)-U50,488 maximally inhibited FSK-stimulated cyclic AMP formation by 25 Ϯ 4% with an EC 50 of 57 Ϯ 3 nM. In the presence of 30 M amitriptyline, the (Ϫ)-U50,488 concentration-response curve was shifted to the right by 7.9-fold, yielding a K i value of 4.3 Ϯ 0.6 M (Fig. 8B) .
Effects of TCAs in CHO/MOR. All the TCAs tested completely displaced specific [ 3 H]diprenorphine bound to -opioid receptors with relatively low potencies (Fig. 9A) . The estimated K i values were amitriptyline, 30 Ϯ 2 M; nortriptyline, 22 Ϯ 3 M; desipramine, 23 Ϯ 4 M; imipramine, 25 Ϯ 3 M; and amoxapine, 44 Ϯ 5 M. Scatchard analysis of [ 3 H]diprenorphine saturation binding data indicated that, at the concentration of 30 M, both amitriptyline and amoxapine decreased the affinity of the radioligand (K D values were control, 118 Ϯ 10 pM; amitriptyline, 370 Ϯ 18 pM, p Ͻ 0.05; amoxapine, 275 Ϯ 15 pM, p Ͻ 0.05) without significantly changing the B max (control, 600 Ϯ 30 fmol/mg protein; amitriptyline, 620 Ϯ 35 fmol/mg protein; amoxapine, 585 Ϯ 29 fmol/mg protein) (Fig. 9B) . In [
35 S]GTP␥S binding assays, the TCAs caused a small and not significant stimulatory effect, which occurred at concentrations greater than 10 M (Fig.  9C) . Under the same conditions, the selective -opioid receptor agonist DAMGO increased (Fig. 9D) .
Discussion
In the present study, we show for the first time that widely used TCAs, such as amoxapine, amitriptyline, nortriptyline, desipramine, and imipramine, exert direct agonist activity at distinct opioid receptor subtypes. In CHO cells individually expressing the human receptors these drugs display differential affinity for ␦-, -, and -opioid receptors. Thus, amoxapine, an antidepressant with rapid onset of therapeutic efficacy and atypical antipsychotic properties, preferentially bound to the ␦-opioid receptor, whereas amitriptyline, nortriptyline, imipramine, and desipramine showed higher selectivity for the -opioid receptor. All the TCAs examined had relatively low affinity for the -opioid receptor. At each opioid receptor subtype, the TCAs completely displaced the specific binding of the radioligands and decreased the affinities of the radioligands without significantly affecting the B max values. These data indicated that TCAs interacted with the opioid receptors as competitive ligands.
In agreement with the radioligand binding data, TCAs showed differential agonist activity at the distinct opioid receptor subtypes. In fact, the drugs stimulated ␦-and -opioid receptors without significant agonist effects at -opioid receptor. Moreover, important differences were observed in jpet.aspetjournals.org the drug potencies and efficacies at ␦-and -opioid receptors. Thus, amoxapine was the most potent and efficacious ␦-opioid receptor agonist but a weak stimulant of -opioid receptors. In contrast, classic TCAs displayed higher potencies at -than ␦-opioid receptors. In line with the present study, Isenberg and Cicero (1984) reported that in rat brain membranes amoxapine inhibited the binding of the ␦-opioid receptor agonist [
3 H][D-Ala 2 ,D-Leu 5 ]enkephalin 5-fold more potently than that of the nonselective opioid receptor ligand [ 3 H]naltrexone. The preferential activity of classic TCAs at -opioid receptors correlates with previous radioligand binding studies reporting a higher selectivity of these drugs for -over -and ␦-opioid binding sites in the human thalamic area (Wahlström et al., 1994) .
The direct agonist activity of amoxapine was characterized at both cloned and native ␦-opioid receptors. In CHO/DOR cells, the drug mimicked the responses to DPDPE in different functional assays, including stimulation of [
35 S]GTP␥S binding, inhibition of cyclic AMP accumulation, activation of the ERK1/2 pathway, and induction of Akt and GSK-3␤ phosphorylations. In addition, amoxapine was capable of activating ␦-opioid receptors endogenously present in rat dorsal striatum and nucleus accumbens and in human frontal cortex, indicating that the agonist activity was not limited to heterologous cell expression systems. Although in CHO/DOR cells amoxapine stimulated [
35 S]GTP␥S binding almost as efficaciously as DPDPE, in all the other functional assays it consistently showed E max values lower than those of the full agonist, indicating a partial agonist activity at the ␦-opioid receptor. Likewise, the maximal responses elicited by classic TCAs at either -or ␦-opioid receptors were significantly lower than those of the corresponding full agonist, suggesting that these drugs also act as partial agonists.
Because TCAs are known to interact with different neurotransmitter receptor systems and to affect several cellular events, it was important to assess the specificity of their agonist activity. In CHO/DOR cells and rat and human brain, the amoxapine responses were completely blocked by low nanomolar concentrations of NTI, indicating the involvement of ␦-opioid receptors. With regard to the classic TCAs, in CHO/DOR cells the stimulation of [ 35 S]GTP␥S binding was totally blocked by NTI, and in CHO/KOR cells both stimulation of [
35 S]GTP␥S binding and inhibition of cyclic AMP accumulation were completely antagonized by nor-BNI, indicating that the effects were specifically mediated by either ␦-or -opioid receptors, respectively. The stimulations of ERK1/2 phosphorylation by amitriptyline observed in CHO/ DOR, CHO/KOR, and C6 glioma cells were largely reduced by the opioid receptor antagonists but not completely antagonized, particularly at concentrations of the antidepressant higher than 10 to 15 M. This indicates that amitriptyline could also induce ERK1/2 phosphorylation through an opioid receptor-independent mechanism. The molecular events mediating the latter effect are still unknown and require further investigation.
TCAs are known to accumulate in the brain where they reach concentrations severalfold higher than those in the blood. The plasma concentrations of the TCAs tested range from 0.2 to 1.6 M (Baldessarini, 2006) , whereas their brainto-plasma ratios have been reported to be 10 to 35:1 (Glotzbach and Preskorn, 1982) . In rats, the administration of 10 to 15 mg/kg desipramine or 20 mg/kg amoxapine produced brain concentrations equal to 20 to 40 M and 13 M, respectively (Biegon and Samuel, 1980; Kobayashi et al., 1992) . Thus, the observed potencies of TCAs as ␦-and -opioid receptor agonists are consistent with the brain concentrations reached by these drugs at clinically relevant doses.
The present demonstration that TCAs directly stimulate ␦-and -opioid receptors raises the possibility that this property may contribute to their analgesic activity. Acute and chronic administrations of TCAs have been shown to display antinociceptive properties in various acute experimental pain models both in animals and humans, and in several of these tests a sensitivity to blockade by naloxone has been observed (Micó et al., 2006) . Recent studies have highlighted the participation of distinct opioid receptor subtypes. Thus, in the acetic acid-induced abdominal constriction test, the analgesic effect of amitriptyline was more potently antagonized by NTI than naloxone, indicating the preferential involvement of ␦-opioid receptors (Gray et al., 1998) . The antiallodynic properties of chronic nortriptyline treatment was absent in mice deficient of ␦-opioid receptors (Benbouzid et al., 2008b) , and both ␦-and -opioid receptor antagonists blocked the attenuation of neuropathic allodynia elicited by chronic TCA treatment (Benbouzid et al., 2008a) . Moreover, supraspinal ␦-and spinal -opioid receptors have been proposed to be involved in the antihyperalgesic effect of chronically administered clomipramine in a mononeuropathic pain model in rats (Marchand et al., 2003) . Although it is possible that these effects may result from indirect actions of TCAs on the opioidergic system (i.e., enhanced release of endogenous opioid peptides), the present data support the idea that at least a portion of the TCA analgesic effect may involve a direct agonist activity at ␦-and -opioid receptors. This direct mechanism may operate in conjunction with the primary action of these drugs on noradrenergic and serotoninergic systems (Micó et al., 2006) .
It is also possible that the opioid agonist activity of TCAs, particularly at ␦-opioid receptors, may contribute to their mood-elevating effects. Genetic and pharmacological studies have shown that ␦-opioid receptors exert antidepressant activity (Filliol et al., 2000; Jutkiewicz, 2006) . Cellular studies have reported that activation of ␦-opioid receptors induces mitogenic responses (Wilson et al., 1997) and promotes neuroprotection and neurogenesis (Narita et al., 2006) , which seem to be critical for the action of antidepressants (Duman et al., 2000) . At the molecular level, these neurotrophic effects occur through recruitment of downstream intracellular molecules and phosphorylation events, particularly those associated with ERK1/2 and Akt/GSK-3␤ signaling pathways (Tegeder and Geisslinger, 2004) , which, as shown in the present study, can be regulated by TCAs via activation of ␦-and -opioid receptors. Moreover, both ERK1/2 and GSK-3␤ have been linked to the action of antidepressants (Jope and Roh, 2006; Duman et al., 2007) . In C6 glioma cells, amitriptyline and other TCAs have been recently reported to regulate the production of glial cell line-derived neurotrophic factor, a stimulant of adult neurogenesis, by activating ERK1/2 (Hisaoka et al., 2007) . Because the present study shows that in these cells amitriptyline-induced ERK1/2 stimulation is largely mediated by stimulation of -opioid receptors, it is possible that this receptor system also participates in TCA regulation of the synthesis of glial cell line-derived neurotrophic factor and other neurotrophic factors. 
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The agonist activity at ␦-and -opioid receptors may also be involved in some TCA adverse effects. For example, the administration of nonpeptidic ␦-opioid agonists is known to cause seizure in laboratory animals (Jutkiewicz, 2006) , whereas activation of -opioid receptors may exert anticonvulsant activity (Loacker et al., 2007) . In this context, the higher potency and efficacy of amoxapine at ␦-versus -opioid receptors may correlate with the observed greater risk of seizure associated with amoxapine overdose, compared with other antidepressants (Litovitz and Troutman, 1983) . TCAs are also known to induce a dysphoric-agitated state in some patients (Baldessarini, 2006) . In animal models, the administration of -opioid receptor agonists has been reported to lower mood and exert prodepressive effects, whereas antagonists produce anxiolytic and antidepressant actions (Mague et al., 2003) . Moreover, distinct stress-induced behavioral responses have been shown to be antagonized by -opioid receptor blockers or deletion of the prodynorphin gene, suggesting that dynorphin stimulation of -opioid receptors may mediate stress-induced dysphoria (McLaughlin et al., 2003) . Thus, the -opioid agonist activity may be related to TCAinduced mood worsening and anxiogenic reactions. However, there is also evidence that activation of -opioid receptors produces anxiolytic-like behavior (Wall and Messier, 2000) .
Moreover, the present study shows that in rat nucleus accumbens amitriptyline behaves as partial agonist at -opioid receptors and antagonizes the action of the full agonist (Ϫ)-U50,488. Thus, it is possible that in stress-related conditions, where an intense release of dynorphin can overstimulate -opioid receptors, the partial agonist activity of TCAs may reduce the level of receptor activation, thus attenuating, rather than enhancing, the aversive emotional consequences of increased -opioid transmission.
